Loading…
Harmony Biosciences Holdings, Inc. is projected to rise to $51.64 by 2027, a +40% move from its current price of $36.84. HRMY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $36.18 | $36.86 | $37.56 | +0.06% |
| Jul 15 | $35.92 | $36.88 | $37.88 | +0.12% |
| Jul 16 | $35.72 | $36.90 | $38.13 | +0.18% |
| Jul 17 | $35.56 | $36.93 | $38.34 | +0.23% |
| Jul 18 | $35.43 | $36.95 | $38.53 | +0.29% |
| Jul 19 | $35.31 | $36.97 | $38.71 | +0.35% |
| Jul 20 | $35.20 | $36.99 | $38.88 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $35.20 | $36.99 | $38.88 | +0.41% |
| Week 2 | $34.62 | $37.14 | $39.85 | +0.82% |
| Week 3 | $34.22 | $37.29 | $40.65 | +1.23% |
| Week 4 | $33.90 | $37.45 | $41.36 | +1.65% |
| Week 5 | $33.64 | $37.60 | $42.02 | +2.07% |
| Week 6 | $33.43 | $37.76 | $42.65 | +2.48% |
| Week 7 | $33.24 | $37.91 | $43.24 | +2.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Harmony Biosciences Holdings, Inc. is a healthcare company described as a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
The company also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome.
Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc.
in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc. (HRMY) operates in the Healthcare sector as a commercial-stage pharmaceutical company focused on therapies for rare neurological diseases in the United States. The stock trades at $38.26 per share, with a market capitalization of $2.21B and a ranking position of 1974.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 3.9% above — a clean break opens room to run.
A major ceiling 15.9% above — clearing it would confirm fresh momentum.
Key HRMY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HRMY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.68 | Sell | $37.39 | Sell |
| MA 10 | $36.89 | Sell | $36.82 | Buy |
| MA 20 | $35.49 | Buy | $35.71 | Buy |
| MA 50 | $33.08 | Buy | $33.77 | Buy |
| MA 100 | $31.09 | Buy | $32.88 | Buy |
| MA 200 | $32.45 | Buy | $32.82 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.64 | Neutral |
| Stoch RSI (14) | 28.40 | Neutral |
| CCI (20) | 63.62 | Neutral |
| Williams %R (14) | -29.40 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 7.85 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 70.60 | Neutral |
| TRIX (15) | 0.55 | Buy |
| Awesome (5,34) | 3.67 | Buy |
| Ultimate (7,14,28) | 60.31 | Neutral |
| Momentum (10) | 2.71 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 38.27 | Sell |
| ADX (14) | 27.65 | Buy |
| ATR (14) | 0.63 | Info |
The 30-day technical picture shows bullish sentiment with RSI14 at 70 and key moving averages near the current price. The 50-day simple moving average is $32.68 and the 200-day simple moving average is $32.37, indicating a constructive short-term trend. Support sits at $30.09 while resistance is at $38.26, with the 30-day price range spanning from $33.81 to $43.30.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.54 | $36.84 | $47.90 | 0% | Neutral | |
| $42.29 | $51.64 | $65.92 | +40% | Bullish | |
| $50.77 | $63.16 | $82.80 | +71% | Bullish | |
| $59.37 | $75.00 | $100.42 | +104% | Bullish | |
| $64.61 | $82.71 | $112.75 | +125% | Bullish | |
| $66.68 | $86.40 | $119.64 | +135% | Bullish | |
| $79.73 | $104.48 | $146.73 | +184% | Bullish | |
| $93.06 | $123.24 | $175.31 | +235% | Bullish | |
| $105.13 | $140.61 | $202.41 | +282% | Bullish | |
| $121.39 | $163.88 | $238.54 | +345% | Bullish | |
| $189.90 | $267.41 | $407.90 | +626% | Bullish | |
| $326.15 | $492.55 | $805.36 | +12.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.54 | $36.84 | $43.63 | +0.00% |
| August 2026 | $32.50 | $38.04 | $45.49 | +3.27% |
| September 2026 | $33.04 | $38.86 | $46.83 | +2.14% |
| October 2026 | $32.33 | $38.18 | $46.32 | -1.74% |
| November 2026 | $32.06 | $38.00 | $46.35 | -0.48% |
| December 2026 | $32.86 | $39.07 | $47.90 | +2.83% |
Click any year to see its month-by-month HRMY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect HRMY to range from $26.54 to $47.90 through 2026. The $36.84 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The HRMY price prediction for 2027 points to an average of $51.64 (low $42.29, high $65.92) — a potential gain of +40% on today's $36.84. Momentum favours further upside here.
In 2028, HRMY is projected to trade between $50.77 and $82.80, averaging $63.16 — a potential gain of +71% from today's $36.84. That is up +22% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Harmony Biosciences Holdings, Inc.'s 2029 outlook centres on $75.00, within a $59.37 to $100.42 range. That is up +19% on the projected 2028 average. That marks a +104% change versus current levels. Momentum favours further upside here.
By 2030, HRMY could reach as high as $112.75, with a base case around $82.71 and support toward $64.61 — roughly +125% from $36.84. Buyers look set to stay in control over this stretch.
Expect HRMY to range from $66.68 to $119.64 through 2031. The $86.40 average target implies a +135% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The HRMY price prediction for 2032 points to an average of $104.48 (low $79.73, high $146.73) — a potential gain of +184% on today's $36.84. Buyers look set to stay in control over this stretch.
In 2033, HRMY is projected to trade between $93.06 and $175.31, averaging $123.24 — a potential gain of +235% from today's $36.84. That is up +18% on the projected 2032 average. Momentum favours further upside here.
Harmony Biosciences Holdings, Inc.'s 2034 outlook centres on $140.61, within a $105.13 to $202.41 range. That is up +14% on the projected 2033 average. That marks a +282% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, HRMY could reach as high as $238.54, with a base case around $163.88 and support toward $121.39 — roughly +345% from $36.84. Momentum favours further upside here.
Expect HRMY to range from $189.90 to $407.90 through 2040. The $267.41 average target implies a +626% move from current prices. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The HRMY price prediction for 2050 points to an average of $492.55 (low $326.15, high $805.36) — a potential gain of +12.4x on today's $36.84. Momentum favours further upside here.
Investing $1,000 in HRMY today (≈ 27.144408 HRMY) could be worth
$13,370.1
+$12,370.1 (+1237%) by 2050 · US Dollar
Based on the average projected HRMY price of $492.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HRMYwould be worth at today's price.
$1,000 invested in HRMY on Jul 10, 2025 (≈ 29.12904 HRMY) would be worth
$1,073.11
+$73.11 (+7.3%) today · 1.07× · US Dollar
Based on a HRMY entry price of $34.33 vs. today's $36.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.26 | $988.73 | -1.1% |
| 1 month ago | $35.48 | $1,038.33 | +3.8% |
| 3 months ago | $28.89 | $1,275.18 | +27.5% |
| 6 months ago | $38.27 | $962.63 | -3.7% |
| 1 year ago | $34.33 | $1,073.11 | +7.3% |
| All time (5.0y) ago | $29.22 | $1,260.78 | +26.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HRMY forecast.
Our base-case forecast reaches $74.00 around 2029.
Implied market cap at $74.00: $4.28B
The multi-year forecast paints a strong upside path, with the 2026 average price listed as $38.26 and the 2026 minimum of $26.54 and maximum of $50.59. By 2027 the average is $55.71 with a bullish sentiment and a 45.6 ROI; 2028 shows an average of $69.32 and an 81.2 ROI; 2029 an average of $83.20 with a 117.5 ROI; 2030 an average of $92.76 with a 142.4 ROI. The trajectory continues through 2031 and beyond, with 2032 at $121.40 (217.3 ROI), 2033 at $144.89 (278.7 ROI), 2034 at $166.58 (335.4 ROI), 2035 at $195.58 (411.2 ROI), 2040 at $330.97 (765 ROI), and 2050 at $626.98 (1538.7 ROI), all labeled bullish.
The forecast max values reach $126.46 by 2030, $504.89 by 2040, and $1,025.23 by 2050. The indicated annualized volatility is 40%. These figures are estimates and not guarantees, and the sentiment shifts from Neutral in 2026 to Bullish from 2027 onward.
Tap a question to reveal the answer.
The 2030 forecast shows min $72.45, avg $92.76, max $126.46, ROI 142.4, sentiment BULLISH.
From 2027 onward the forecast is BULLISH with positive ROI: 45.6 (2027), 81.2 (2028), 117.5 (2029), 142.4 (2030), 158.4 (2031), 217.3 (2032), 278.7 (2033), 335.4 (2034), 411.2 (2035), 765 (2040), and 1538.7 (2050). These are estimates, not guarantees.
Yes. The forecast max by 2030 is $126.46; by 2035 it is $284.71; by 2040 it is $504.89; by 2050 it is $1,025.23.
The 2026 average is $38.26 (the current price). The 2027 average is $55.71, and subsequent years show higher averages, indicating the price could exceed the current level from 2027 onward.
The 30-day range is $33.81 to $43.30. RSI14 is 70. The 50-day SMA is $32.68 and the 200-day SMA is $32.37. Support is at $30.09 and resistance at $38.26.
Harmony Biosciences Holdings, Inc. Community Discussion
0Share your Harmony Biosciences Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.